title: Biochemical relapse following radical prostatectomy and miR-200a levels in prostate cancer.
abstract: BACKGROUND
  Radical prostatectomy cures the majority of men with clinically localized disease, but up to 30% of men relapse with rising serum PSA levels. Stage, Gleason grade, and pre-operative PSA levels are associated with outcome but do not accurately predict which individuals will relapse. MicroRNA (miRNA) levels are altered in cancer and are associated with progression of disease. The miR-200 family has roles in prostate cancer.
  
  
  METHODS
  miR-200a levels were measured in 18 radical prostatectomy samples from men who did not relapse and from 18 who did relapse, matched for stage (all T3), grade, and PSA levels. A pair of cancer and normal prostate cell lines derived from the same radical prostatectomy specimen were transfected with miR-200a to determine the effects on growth, wound healing, and invasion.
  
  
  RESULTS
  Comparing the matched samples, 11 of the relapsers contained lower, 2 higher and 5 similar levels to the non-relapsers. Transient transfection of miR-200a significantly reduced cell proliferation in prostate cancer cell lines but did not affect invasiveness.
  
  
  CONCLUSIONS
  miR-200a overexpression reduced prostate cancer cell growth and may have potential, in combination with other markers, in stratifying prostate cancer patients for more intensive monitoring and therapy.
authors.affiliation: National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland. niall.barron@dcu.ie
authors.forename: Niall
authors.initials: N
authors.lastname: Barron
authors.forename: Joanne
authors.initials: J
authors.lastname: Keenan
authors.forename: Patrick
authors.initials: P
authors.lastname: Gammell
authors.forename: Vanesa G
authors.initials: VG
authors.lastname: Martinez
authors.forename: Alex
authors.initials: A
authors.lastname: Freeman
authors.forename: John R
authors.initials: JR
authors.lastname: Masters
authors.forename: Martin
authors.initials: M
authors.lastname: Clynes
mesh_terms: D002460:Cell Line; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000096:biosynthesis / Q000235:genetics*; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000235:genetics*; D011467:Prostate / Q000378:metabolism*; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000235:genetics* / Q000601:surgery; D014162:Transfection
chemical_list: C533896:MIRN200 microRNA, human; D035683:MicroRNAs; D017430:Prostate-Specific Antigen